Technologies

Organotypic models of ovarian cancer are 3D models containing defined extracellular matrices, such as collagen and fibronectin, ovarian cancer cells with specific genetic/molecular characteristics, and one or more cancer-associated stromal cell types (fibroblasts, mesothelial cells, endothelial cells) to mimic specific metastatic niches of ovarian cancer (omentum, peritoneum, interstitial stroma) and the complex interactions within tumor tissues.

The development of genome editing tools has revolutionized the way we think and deal with genetics. The use of Cas9 or its variants allows modifications of specific sites in the human genome by inducing deletions and insertions in a more or less controlled way. In recent years, a new class of tools for genome editing has emerged: the base editors (BE), which result from the fusion of a modified Cas9, which serves to direct the BE to the target, and an active deaminase acting on the DNA, which mediates the C> T or A> G editing.

Aptamers, short structured single-stranded oligonucleotides binding at high affinity to a given target protein, are selected from large combinatorial libraries through repeated cycles of incubation of the library with the target, recovery and amplification of target-bound oligonucleotides (SELEX technology, Systematic Evolution of Ligands by EXponential enrichment). SELEX can be applied to select aptamers against a known target protein or against a specific cell phenotype, without any prior knowledge of the specific target, leading to new biomarkers discovery.

Nowadays, to properly design and develop advanced materials capable to preserve for long times their performance under aggressive environments such as power generation plants, renewables, nuclear reactors and electronics of new generation, transport on ground and on space, aeronautics, catalysis, biomedical implants, the optimization of metallurgical processes involved is crucial.

The final technology will add polarimetric capability to imaging cameras in the NUV/optical, providing simultaneous measurements of the different polarization states of the light. This will be obtained by the development of an innovative coating based on nanostructured emissive materials sensitive to the polarization of the incident light. A  double layer film of two organic systems will be coupled to image detectors so that the two polarization components of the incoming light are converted into two different colors.

The assessment of bio-humoral markers beyond clinical evaluation would allow a more comprehensive pheno/endotyping of patients affected by chronic inflammatory diseases. Therapy personalization would require a profile of the mediators that are relevant in the disease pathogenesis and that well correlate with prognosis. Currently, the measurement of multiple biomarkers is not included in patient evaluation because it has high costs,  requires centralized laboratories, experienced personnel and bulky equipment and is time-consuming.

The proposed technology takes advantages of the huge potentialities of the gellan gum microgels in the preservation of cultural heritage. Microgels are polymeric gels particles with the micro and nanoscale size, whose soft nature is due to the presence of the aqueous solvent inside the particle. For their small size, they can easily diffuse in the environment and penetrate in the porous structure of paper and wood to act as cleaner agent.

Our idea come from the improving of the traceability technique in agro-food fisheries industries through the application of omics technologies in microbiota studies.  These latter would be capable of exploiting the huge pool of biological molecules contained in fishery resources (e.g. nucleic acids, proteins, metabolites) and use them as a powerful tools for the identification and reconstruction of fishery history, from the sea to the table.

Integrative omics has posed new challenges in modern precision medicine, particularly in oncology, including i) the identification of new tumor markers for early, precise, and non-invasive diagnostics, and ii) the discovery of innovative molecular targets for therapeutic applications. Our studies on medulloblastoma, a highly malignant childhood tumor, have contributed to identifying RNA molecules that meet these criteria.

In our recent publication we identified a group of  bladder cancer-specific ncRNA, called T-UCRs that are the most up-regulated in bladder cancer patient samples compared with normal bladder urothelium.

The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples).

An innovative approach for the treatment of diabetic and venous ulcers, characterized by a difficult healing process and therefore at potential risk of infection and therefore of hospitalization and amputation of the limb, is represented by the local administration of "bioactive" factors through the use of synthetic and/or biological matrices that allow a gradual and controlled release in order to obtain a better and faster healing.

The object of the technology is the development of a transferable methodology from the laboratory scale to the pilot scale to be validated in the industrial setting for the treatment of basic waste of natural polymers of agro-food or manufacturing industry.

The instrumentation is based on the electrical resistivity tomography (ERT) which is a non-invasive geophysical technology used to obtain information on anomalous bodies possibly present in the subsoil. The theoretical basis lies in the different electrical properties of the lithotypes present in the subsoil.

We have identified the presence of the poorly characterized precursor proNGF-A in human tissues, deposited its coding nucleotide sequence (GenBank MH358394) and demonstrated its neuroprotective and neurotrophic activity in vitro and in vivo. We inserted mutations into the native molecule, identified through computational analysis, which allow proNGF-A production by eukaryotic expression systems, through a method currently validated on a laboratory scale.